| Literature DB >> 35769088 |
Maria Krajewska1, Ewelina Witkowska-Sędek1, Małgorzata Rumińska1, Anna Stelmaszczyk-Emmel2, Maria Sobol3, Anna Majcher1, Beata Pyrżak1.
Abstract
Background: Obesity is related to changes in adipokine secretion, activity of adipose tissue macrophages, helper T cells, and regulatory T cells. It has been confirmed that vitamin D has potent anti-inflammatory properties. It contributes to reduction in pro-inflammatory mediators and an increase in anti-inflammatory cytokines. There is also evidence that vitamin D could decrease C-reactive protein (CRP) and affect selected haematological indices. Aim of the Study: We aimed to evaluate the effect of vitamin D on interleukin (IL)-10, IL-17, CRP, blood leukocyte profile, and platelet (PLT) count in overweight and obese children before and after six months of vitamin D supplementation. Material andEntities:
Keywords: C-reactive protein; blood leukocyte profile; children; interleukin-10; interleukin-17; obesity; platelets; vitamin D
Mesh:
Substances:
Year: 2022 PMID: 35769088 PMCID: PMC9235399 DOI: 10.3389/fendo.2022.920340
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Baseline anthropometric measurements, haematological, and biochemical parameters in the study group and in the control group.
| p value | STUDY GROUP | CONTROL GROUP |
|---|---|---|
| (n = 67) | (n = 31) | |
| 13.3 ± 2.11 | 13.8 ± 2.45 | |
| ns | ||
| 0.7 ± 1.26 | -0.6 ± 1.37 | |
| < 0.001 | ||
| 2.3 ± 0.66 | -0.3 ± 1.09 | |
| < 0.001 | ||
| 91.3 ± 10.17 | 62.3 ± 6.49 | |
| <0.001 | ||
| 106.1 ± 10.48 | 78.7 ± 8.86 | |
| < 0.001 | ||
| 0.9 ± 0.06 | 0.8 ± 0.04 | |
| < 0.001 | ||
| 0.9 ± 2.68 | 0.4 ± 0.03 | |
| < 0.001 | ||
| 36.9 ± 6.12 | 22.7 ± 6.06 | |
| < 0.001 | ||
| 2.3 ± 0.46 | -0.2 ± 0.83 | |
| < 0.001 | ||
| 15.9 (12.6 – 20.0) | 23.9 (17.7 – 29.9) | |
| < 0.001 | ||
| 6.7 (5.5 – 8.1) | 5.7 (5.0 – 6.7) | |
| 0.014 | ||
| 3.2 (2.4 – 4.5) | 2.8 (1.9 – 3.7) | |
| 0.015 | ||
| 0.5 (0.5 – 0.7) | 0.4 (0.4 – 0.6) | |
| 0.009 | ||
| 2.4 (2.1 – 2.9) | 2.2 (1.9 – 2.9) | |
| ns | ||
| 270 (236 – 302) | 260 (231 – 284) | |
| ns | ||
| 0.5 (0.5 – 0.7) | 0.5 (0.5 – 0.5) | |
| 0.003 | ||
| 1.25 (0.03 – 1.74) | 0.65 (0.19 – 1.15) | |
| ns | ||
| 0.05 (0.0 – 0.13) | 0.05 (0.0 – 0.12) | |
| ns |
Data are presented as means ± standard deviations score or as median with interquartile range, as appropriate. SDS, standard deviation score; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio; % FAT (skinfolds), percentage of body fat estimated from skinfolds; BMI, body mass index; 25(OH)D, 25-hydroxyvitamin D; WBC, white blood cells; PLT, platelets; CRP, C-reactive protein; IL-10, interleukin-10; IL-17, interleukin-17; ns, not significant.
Figure 1Correlation between baseline 25(OH)D levels and baseline BMI SDS in the whole study group.
Figure 2Distribution of vitamin D values in the subgroup with severe 25(OH)D deficiency and CRP <= 0.5.
Figure 3Distribution of vitamin D values in the subgroup with severe 25(OH)D deficiency and CRP > 0.5.
Figure 4Correlation between baseline IL-17 levels and baseline monocyte count in the whole study group.
Comparison between anthropometric measurements, haematological, and biochemical parameters in the study group at baseline and after six months of vitamin D supplementation.
| p value | BASELINE | SIX MONTHS |
|---|---|---|
| 0.7 ± 1.26 | 0.6 ± 1.25 | |
| ns | ||
| 2.3 ± 0.66 | 2.2 ± 0.75 | |
| 0.047 | ||
| 91.3 ± 10.17 | 90.6 ± 11.06 | |
| ns | ||
| 106.1 ± 10.48 | 106.4 ± 11.71 | |
| ns | ||
| 0.9 ± 0.06 | 0.9 ± 0.05 | |
| ns | ||
| 0.9 ± 2.68 | 0.5 ± 0.06 | |
| < 0.001 | ||
| 36.9 ± 6.12 | 34.2 ± 6.34 | |
| < 0.001 | ||
| 40.6 ± 7.59 | 38.3 ± 8.93 | |
| ns | ||
| 2.3 ± 0.46 | 2.2 ± 0.55 | |
| ns | ||
| 15.9 (12.6 – 20.0) | 27.1 (22.9 – 32.6) | |
| < 0.001 | ||
| 6.7 (5.5 – 8.1) | 6.2 (5.6 – 7.8) | |
| ns | ||
| 3.2 (2.4 – 4.5) | 3.3 (2.4 – 4.0) | |
| ns | ||
| 0.5 (0.5 – 0.7) | 0.5 (0.4 – 0.6) | |
| ns | ||
| 2.4 (2.1 – 2.9) | 2.3 (2.0 – 2.8) | |
| ns | ||
| 270 (236 – 302) | 261 (232 – 311) | |
| ns | ||
| 0.5 (0.5 – 0.7) | 0.5 (0.5 – 0.6) | |
| 0.001 | ||
| 1.25 (0.03 – 1.74) | 0.78 (0.34 – 1.58) | |
| ns | ||
| 0.05 (0.0 – 0.13) | 0.04 (0.01 – 0.10) | |
| ns |
Data are presented as means ± standard deviations score or as median with interquartile range, as appropriate. SDS, standard deviation score; WC, waist circumference; HC, hip circumference; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio; %FAT (skinfolds), percentage of body fat estimated from skinfolds; %FAT BIA, percentage of body fat estimated using bioelectrical impedance analysis method; BMI, body mass index; 25(OH)D, 25-hydroxyvitamin D; WBC, white blood cells; PLT, platelets; CRP, C-reactive protein; IL-10, interleukin-10; IL-17, interleukin-17; ns, not significant.